Sentences with phrase «of alendronate»

90, No. 3 1294 - 1301 Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy Clarita V. Odvina, Joseph E. Zerwekh, D. Sudhaker Rao, Naim Maalouf, Frank A. Gottschalk and Charles Y. C. Pak

Not exact matches

From a base group of over 400,000 elderly patients, 1802 were prescribed alendronate after starting treatment with the cortisone preparation prednisolone in tablet form.

The group with matched controls, which also consisted of 1802 people, took prednisolone tablets, but did not receive the protective alendronate treatment.

Doctors commonly treat hyperparathyroidism using a class of prescription drugs called bisphosphonates, including alendronate (marketed under the brand name Fosamax) and ibandronate (Boniva), which are supposed to strengthen bones.

The investigated cohort consisted of 1802 patients with oral prednisolone and alendronate treatment and 1802 matched controls, selected from 6076 patients with oral prednisolone but without alendronate treatment (Figure 1 and Figure 2).

In an unadjusted Cox model, alendronate treatment was associated with lower of risk of hip fracture (hazard ratio [HR], 0.35; 95 % CI, 0.23 - 0.55), and the risk estimate did not substantially change in multivariable - adjusted Cox models (Table 2 and Figure 3).

Alendronate treatment was not associated with increased risk of mild upper gastrointestinal tract symptoms (alendronate vs no alendronate, 15.6 [95 % CI, 11.6 - 21.0] vs 12.9 [95 % CI, 9.3 - 18.0] per 1000 person - years; P =.40) or peptic ulcers (10.9 [95 % CI, 7.7 - 15.5] vs 11.4 [95 % CI, 8.0 - 16.2] per 1000 person - yearAlendronate treatment was not associated with increased risk of mild upper gastrointestinal tract symptoms (alendronate vs no alendronate, 15.6 [95 % CI, 11.6 - 21.0] vs 12.9 [95 % CI, 9.3 - 18.0] per 1000 person - years; P =.40) or peptic ulcers (10.9 [95 % CI, 7.7 - 15.5] vs 11.4 [95 % CI, 8.0 - 16.2] per 1000 person - yearalendronate vs no alendronate, 15.6 [95 % CI, 11.6 - 21.0] vs 12.9 [95 % CI, 9.3 - 18.0] per 1000 person - years; P =.40) or peptic ulcers (10.9 [95 % CI, 7.7 - 15.5] vs 11.4 [95 % CI, 8.0 - 16.2] per 1000 person - yearalendronate, 15.6 [95 % CI, 11.6 - 21.0] vs 12.9 [95 % CI, 9.3 - 18.0] per 1000 person - years; P =.40) or peptic ulcers (10.9 [95 % CI, 7.7 - 15.5] vs 11.4 [95 % CI, 8.0 - 16.2] per 1000 person - years; P =.86).

Among the 3604 patients using prednisolone, there was no difference in medication possession ratio of acetylsalicylic acid (analysis of healthy adherer effect)(eFigure 3 in the Supplement; P =.91) between patients with or without alendronate treatment.

After a median follow - up of 1.32 years (interquartile range, 0.57 - 2.34 years), there were 27 hip fractures in the alendronate group and 73 in the no - alendronate group, corresponding to incidence rates of 9.5 (95 % CI, 6.5 - 13.9) and 27.2 (95 % CI, 21.6 - 34.2) fractures per 1000 person - years, with an absolute rate difference of − 17.6 (95 % CI, − 24.8 to − 10.4).

The median alendronate medication possession ratio since prednisolone treatment start was 88 % and the median time delay from start of prednisolone to alendronate initiation was 3.9 (interquartile range, 0.5 - 20.0) months.

There were 27 hip fractures in the alendronate group and 73 in the alendronate - untreated group, corresponding to incidence rates of 9.5 (95 % CI, 6.5 - 13.9) and 27.2 (95 % CI, 21.6 - 34.2) fractures per 1000 person - years, with an absolute rate difference of − 17.6 (95 % CI, — 24.8 to — 10.4)(Table 2).

The researchers created a hybrid compound from 2 molecules: LLP2A, a protein - like molecule that sticks to α4β1 integrins, and alendronate, an osteoporosis drug that sticks to the outer surface of bones.

What the alendronate drugs do is by stopping the normal breakdown of bones, they favor the buildup of old bone that becomes brittle over time and becomes so hard and dense that the normal blood supply can not get into the bone.

This study evaluated the effectiveness of Fosamax (alendronate) as a palliative therapy for osteosarcoma in Irish Wolfhounds.

Fosamax is the brand name for alendronate, a type of bisphosphonate drug that is manufactured by Merck & Co..

The women taking bisphosphonates, namely Fosamax (alendronate), had a 32 percent reduction in their rate of invasive breast cancer compared to women who were not taking one of these drugs.